Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

Blood

Volumn 124, Issue 18, 2014, Pages 2820-2823

  Scheinberg, Phillip ^a,b   Townsley, Danielle ^a   Dumitriu, Bogdan ^a   Scheinberg, Priscila ^a   Weinstein, Barbara ^a   Daphtary, Maithili ^a   Rios, Olga ^a   Wu, Colin O ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Hospital São José   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BLOOD CELL COUNT; CAUSE OF DEATH; CLINICAL ARTICLE; CLONAL EVOLUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GRANULOCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; LEUKEMIA; LOW DRUG DOSE; MONOSOMY 7; MYCOSIS; NECROTIZING FASCIITIS; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RELAPSE; SEPTICEMIA; TREATMENT FAILURE; TREATMENT RESPONSE; ANEMIA, APLASTIC; CELL CLONE; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL; DOSE RESPONSE; RECURRENT DISEASE; SURVIVAL RATE;

ANEMIA, APLASTIC; CHILD; CLONE CELLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUTROPENIA; RECURRENCE; SURVIVAL RATE; VORICONAZOLE;

EID: 84908636795     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-573642     Document Type: Article

References (23)

1. Scheinberg P, Nunez O, Weinstein B., et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011; 365(5): 430-438.
2. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012; 120(6):1185-1196.
3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006; 108(8):2509-2519.
4. Kojima S, Hibi S, Kosaka Y., et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96(6):2049-2054.
5. Bacigalupo A, Brand R, Oneto R., et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000; 37(1):69-80.
6. Frickhofen N, Heimpel H, Kaltwasser J.P., Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003; 101(4):1236-1242.
7. Scheinberg P, Nunez O, Wu C., Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol. 2006; 133(6):606-611.
8. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009; 94(3): 348-354.
9. Scheinberg P, Nunez O, Weinstein B., Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012; 119(2):345-354.
10. Baran DT, Griner PF, Klemperer MR. Recovery from aplastic anemia after treatment with cyclophosphamide. N Engl J Med. 1976; 295(27): 1522-1523.
11. Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010; 115(11): 2136-2141.
12. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000; 356(9241): 1554-1559.
13. Zhang F, Zhang L, Jing L., et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol. 2013; 41(4):328-334.
14. Valdez JM, Scheinberg P, Nunez O., Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011; 52(6):726-735.
15. Rosenfeld S, Follmann D, Nunez O., Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-1135.
16. Ngamjanyaporn P, Thakkinstian A, Verasertniyom O., et al. Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatol Int. 2011; 31(9): 1215-1218.
17. Nakajima M, Komagata S, Fujiki Y., et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007; 17(6):431-445.
18. Weinberger M, Elattar I, Marshall D., et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore). 1992; 71(1):24-43.
19. Trifilio S, Singhal S, Williams S., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007; 40(5):451-456.
20. Trifilio S, Pennick G, Pi J., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007; 109(8): 1532-1535.
21. Cruciani M, Malena M, Bosco O., Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol. 2003; 21(22):4127-4137.
22. Williams DA, Bennett C, Bertuch A., et al. Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatr Blood Cancer. 2014; 61(5):869-874.
23. Dufour C, Svahn J, Bacigalupo A; Severe Aplastic Anemia-Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013; 48(2):174-177.